JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 23 March 2006. doi:10.1136/jcp.2005.033100
Journal of Clinical Pathology 2006;59:912-915
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jcp.2005.033100v1
59/9/912    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Speers, A G
Right arrow Articles by Cooper, A J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speers, A G
Right arrow Articles by Cooper, A J

ORIGINAL ARTICLE

Furosemide reverses multidrug resistance status in bladder cancer cells in vitro

A G Speers1, B A Lwaleed2, J M Featherstone2, B J Sallis1, A J Cooper1

1 Department of Biomedical Sciences, University of Portsmouth, Portsmouth, UK
2 Department of Urology, Southampton University Hospitals NHS Trust, Southampton, UK

Correspondence to:
B A Lwaleed
Department of Urology, Central block, Level E, West Wing, Mailpoint 67, Southampton University Hospitals NHS Trust, Tremona Road, Southampton, SO16 6YD, UK; bashir{at}soton.ac.uk Background: Multidrug resistance (MDR) has a potentially serious influence on cancer treatment and should be taken into consideration in the design and application of therapeutic regimens. It is mediated through the activity of cellular pumps.

Aim: To investigate whether furosemide, itself a pump-blocker, reverses MDR in an in vitro model.

Materials and methods: An MDR bladder cancer cell line (MGH-u 1R) and its parental (drug sensitive) clone were exposed to epirubicin and furosemide, with the concentration of one drug fixed and that of the other serially diluted in a 96-well plate format. Both drugs formed the variable component in separate experiments. After a 1-h exposure, the cells were washed and replenished with fresh medium. To examine the toxicity of epirubicin and furosemide separately and in combination, monotetrazolium-based assays were carried out. Intracellular epirubicin distribution was assessed by confocal microscopy as a second index of resistance status after in vitro exposure.

Results: MGH-u 1R cells incubated with furosemide showed distribution of drug similar to that in the parental cells (MGH-u 1 sensitive). Controls (without furosemide) continued to show a resistant pattern of fluorescence. In cytotoxicity assays furosemide appeared substantially non-toxic. Resistant cells in the toxicity titration experiments showed increased resistance to levels of furosemide over 500 µg/ml. Parental cells were made only marginally more sensitive against increased background toxicity.

Conclusion: Furosemide is effective in reversing MDR status in bladder cancer cell lines in vitro. It may also have an increment of intrinsic cytotoxicity, but only at higher concentrations. We propose a potential for further investigation of furosemide as an adjunct to chemotherapy for superficial bladder cancer.


Abbreviations: ATP, adenosine triphosphate; MDR, multidrug resistance; MGH-u 1R, MDR bladder cancer cell line; P-gp, P-glycoprotein







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.